HKeyBio Launches Fast-Track NHP Toxicology Program for Early Biotech Safety Screening
Event summary
- HKeyBio launched its NHP Fast-Tox Program on June 24, 2026, offering non-GLP toxicology studies to assess safety risks in non-human primates before formal GLP IND-enabling studies.
- The program supports early tolerability assessment, PK/TK-linked safety evaluation, immune-related risk screening, and pre-GLP dose design for biologics and immunomodulatory drug programs.
- HKeyBio has established over 50 NHP models for autoimmune and allergic diseases and supported more than 500 IND-related studies in the field.
The big picture
HKeyBio's NHP Fast-Tox Program addresses a critical gap in biotech drug development by providing early safety risk assessments before resource-intensive GLP studies. This move aligns with the industry trend toward accelerating preclinical evaluations while managing costs and risks, particularly for autoimmune and allergic disease research.
What we're watching
- Adoption Pace
- How quickly early-stage biotech companies will integrate non-GLP NHP toxicology studies into their development pipelines.
- Data Reliability
- Whether the exploratory data from NHP Fast-Tox will be sufficiently robust to influence pre-GLP dose design decisions.
- Competitive Positioning
- The extent to which HKeyBio's program differentiates it from other preclinical CROs offering similar services.
Related topics